Source link : https://www.newshealth.biz/health-news/one-car-t-cell-therapy-for-multiple-myeloma-tops-another-in-propensity-matched-study/
SAN DIEGO — In a propensity-matched comparison of two CAR T-cell therapies, ciltacabtagene autoleucel (cilta-cel, Carvykti) demonstrated better efficacy than idecabtagene vicleucel (ide-cel, Abecma) for relapsed/refractory multiple myeloma, but had a higher rate of severe toxicity. A chart review of patients treated outside of clinical trials showed that 70% of patients treated with cilta-cel achieved […]
Author : News Health
Publish date : 2024-12-11 20:20:08
Copyright for syndicated content belongs to the linked Source.